To evaluate the effect of intravitreal triamcinolone acetonide on visual acuity in branch retinal vein occlusion. The prospective comparative nonrandomized clinical interventional study included ...

Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol. 2009;147 (5):838-846.

Cite this: Treatment of Branch Retinal Vein Occlusion Induced Macular Edema With Bevacizumab - Medscape - Sep 29, 2008.

Central retinal vein occlusion (CRVO) is an eye condition that affects a vein in the retina. Learn about symptoms, causes, treatments, and more.

To investigate the role of the topographical distribution of temporal retinal vessels in anatomical predisposition to branch retinal vein occlusion (BRVO). Sixty patients with BRVO and 60 control ...

SOUTH SAN FRANCISCO, Calif. — In a phase 3 study, ranibizumab injection improved vision in patients with macular edema due to branch retinal vein occlusion, Genentech announced in a press release.

There are two main types of RVO: branch retinal vein occlusion, which affects an estimated 887,000 people in the U.S. and occurs when one of the four smaller branches of the main central retinal ...

"First Report on Worldwide Prevalence of Retinal Vein Occlusion." ScienceDaily. ScienceDaily, 1 February 2010. <www.sciencedaily.com / releases / 2010 / 02 / 100201113748.htm>.

The approval was based on data from the randomized, double-masked phase 3 BALATON (ClinicalTrials.gov Identifier: NCT04740905) and COMINO (ClinicalTrials.gov Identifier: NCT04740931) studies ...

The sBLA is supported by data from the randomized, multicenter, double-masked phase 3 BALATON (ClinicalTrials.gov Identifier: NCT04740905) and COMINO (ClinicalTrials.gov Identifier: NCT04740931 ...

On Monday Regeneron reported more positive data for its wet AMD/macular edema drug Eylea (aflibercept). This time, it’s in patients with macular edema following branch retinal vein occlusion (BRVO), a ...

Background Branch retinal vein occlusion (BRVO) is a frequent retinal vascular disease with an incidence of 2.14/1000/year in the population over 40 years of age. [1] ...